Tc-DB8
Phase 2Small molecule
Tc-DB8 is one of 17 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Tc-DB8
TTomsk National Research Medical Center of the Russian Academy of Sciences
Phase 2
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Primary Breast Cancer1 trial
SPECT/CT Imaging of Gastrin-releasing Peptide Receptor Expression in Breast Cancer With Different Estrogen Receptor Expression Using Technetium-99m-labelled DB8 [99mTc]Tc-DB8
Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07275463·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tc-DB8. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details